Perceptive Advisors’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Perceptive Advisors’s Portfolio KERX Stock Details KERX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-83,386	Closed	-$388K	–	167
2017 Q4	$388K	Hold	83,386	–	–	0.01%	124
2017 Q3	$592K	Buy	+83,386	New	+$600K	0.02%	115
2015 Q3	–	Sell	-34,380	Closed	-$343K	–	202
2015 Q2	$343K	Sell	34,380 -50,000	-59%	-$536K	0.02%	137
2015 Q1	$1.07M	Buy	+84,380	New	+$1.08M	0.08%	101
2014 Q2	–	Sell	-275,000	Closed	-$4.69M	–	159
2014 Q1	$4.69M	Buy	+275,000	New	+$4.15M	0.49%	47
2013 Q4	–	Sell	-200,000	Closed	-$2.02M	–	142
2013 Q3	$2.02M	Buy	200,000 +150,000	+300%	+$1.33M	0.16%	61
2013 Q2	$374K	Buy	+50,000	New	+$391K	0.04%	70

Other funds holding KERX

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CLM

ClearBridge LLC (Maryland) Baltimore, Maryland $329M AUM 9.73% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's KERX Position: Q1 2018 in Review

Perceptive Advisors sold out of Keryx Biopharmaceuticals Inc (KERX) in Q1 2018, closing a stake of 83,386 shares — an estimated $388K sold.

Perceptive Advisors first reported a position in KERX in Q2 2013 and held it in 7 quarters. The position peaked at $4.69M in Q1 2014. 125 funds tracked by Wall St. Rank hold KERX as of Q1 2018.

Perceptive Advisors reported no remaining Keryx Biopharmaceuticals Inc position as of Q1 2018 after selling out during the quarter.
Perceptive Advisors sold 83,386 Keryx Biopharmaceuticals Inc shares in Q1 2018, an estimated $388K.
Perceptive Advisors first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and held it in 7 quarters.
Perceptive Advisors's Keryx Biopharmaceuticals Inc position peaked at $4.69M in Q1 2014.
125 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q1 2018.

Based on Perceptive Advisors's 13F filing for Q1 2018, filed 15 May 2018.